Bowel Cancer Testing Rates Low in UK, High in France

UK lagging behind with bowel cancer drug test A study funded by Merck Serono (distributors of cetuximab outside of North America; CDx biomarkers for cetuximab = EGFR+ and KRAS-) found that only 44% of all bowel cancer patients in the UK received testing for KRAS...